Sepsis Treatments
Find Sepsis Treatments
Meropenem
View Brand InformationWhat is Meropenem?
Approved To Treat
Related Clinical Trials
Summary: The goal of this clinical trial is to demonstrate the clinical benefit of early intervention with meropenem in adult patients of both sexes with suspected infection and risk of sepsis. The primary objective is to evaluate the clinical benefit of a protein called Pancreatic Stone Protein (PSP), which, if elevated, indicates that patient may be at increased risk of developing sepsis. The secondary o...
Summary: This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.
Summary: The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Related Latest Advances
Brand Information
Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis andpenicillin-susceptible isolates of Streptococcus pneumoniae, in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.
1.2 Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
- Hypersensitivity Reactions
- Severe Cutaneous Adverse Reactions
- Rhabdomyolysi
- Seizure Potential
- Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid
- Clostridioides difficile – Associated Diarrhea
- Development of Drug-Resistant Bacteria
- Overgrowth of Nonsusceptible Organisms
- Thrombocytopenia
- Potential for Neuromotor Impairment
Local adverse reactions that were reported with meropenem for injection were as follows: Inflammation at the injection site (2.4%), injection site reaction (0.9%), phlebitis/thrombophlebitis (0.8%), pain at the injection site (0.4%), and edema at the injection site (0.2%).
Systemic adverse reactions that occurred in greater than 1% of the meropenem for injection-treated patients were diarrhea (4.8%), nausea/vomiting (3.6%), headache (2.3%), rash (1.9%), sepsis (1.6%), constipation (1.4%), apnea (1.3%), shock (1.2%), and pruritus (1.2%). Additional systemic adverse reactions that occurred in less than or equal to 1% but greater than 0.1% of the meropenem for injection-treated patients are listed below within each body system in order of decreasing frequency:
dehydrogenase (LDH), and bilirubin

Manufactured by:
Brooks Steriscience Limited
Gujarat 391243, India (IND)
Revised- 6/2025



